EU Advocate General Urges Annulment of 80% Pharma Funding Rule for Quaternary Wastewater Treatment
The Advocate General's opinion challenges the EU's extended producer responsibility model for micropollutants by questioning the 80% industry funding mandate. It highlights tensions between environmental goals and evidentiary standards for cost allocation. Future rulings may reshape pharma regulatory costs across Europe.
If the Court of Justice follows the recommendation, member states must redesign cost-sharing by 2028, potentially increasing taxpayer exposure or delaying plant upgrades. This could influence parallel U.S. EPA discussions on contaminant candidate lists and global supply-chain pressure on generic manufacturers. Next steps hinge on the full court ruling and subsequent Commission guidance on monitoring standards.
CJEU: Will follow Advocate General recommendation and annul the 80% clause by March 2027.
Sources (2)
- [1]Court of Justice of the European Union Advocate General Opinion(https://curia.europa.eu)
- [2]European Commission Urban Wastewater Treatment Directive Impact Assessment(https://ec.europa.eu/environment/water)